
|Videos|May 31, 2017
Dr. Jun Discusses Cyptogenic Hepatocellular Carcinoma
Author(s)Tomi Jun, MD
Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma.
Advertisement
Tomi Jun, MD, Stanford University School of Medicine, discusses cryptogenic hepatocellular carcinoma (HCC).
Although viral liver diseases are seen as the predominant risk factor of HCC, Jun says, there is a population of patients with cryptogenic HCC—mostly those with non-alcoholic fatty liver disease.
Although patients with cryptogenic HCC show less cirrhosis than HCC caused by viral diseases such as hepatitis B and C, the rate of long-term survival is worse.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC
2
Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer
3
Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer
4
FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations
5




















































